'Striking' Colon Cancer Data Spur Mid-Presentation Ovation at ESMO
(MedPage Today) -- PARIS -- Nearly every single patient with mismatch repair-deficient (dMMR) colon cancer in the NICHE-2 trial achieved a pathologic response with just two cycles of neoadjuvant immunotherapy.
Patients in the single-arm study...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news
More News: Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Gastroenterology | Gastroschisis Repair | Immunotherapy | Neoadjuvant Therapy | Study